Pfizer partners with molecular glue startup Triana in $49M upfront deal

Pfiz­er is deep­en­ing its in­vest­ment in pro­tein de­graders through a new part­ner­ship with Tri­ana Bio­med­i­cines, a start­up work­ing in the trendy field of mol­e­c­u­lar glues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.